Several US Jolly rancher sweets unsafe to eat, FSA says
A number of products from a brand of US sweets are "unsafe to eat" and contain ingredients which could increase the risk of cancer and cause damage to DNA, the Food Standards Agency (FSA) has warned.UK businesses and consumers are being urged to stop buying and selling the Jolly Ranchers products, owned by US company Hershey.The FSA says they contain chemical compounds - mineral oil aromatic hydrocarbons (MOAH) and mineral oil saturated hydrocarbons (MOSH) - which are "not compliant with UK laws".The products pose a safety risk if consumed regularly over time but there is "no immediate cause for concern, as [the] food safety risk is low", the agency adds.
In a food alert published on Wednesday evening, the FSA said: "MOAH can cause damage to DNA and has the potential to increase the risk of cancer, particularly if consumed in high quantities over a prolonged period of time."MOAH is a genotoxic carcinogen, therefore no exposure is without risk to human health."MOAH and MOSH are used in confectionary to prevent stickiness and create a glossy appearance.According to the agency, The Hershey Company has been working with the UK government body to remove the affected Jolly Rancher products from the UK market since 2024, but some businesses in Britain have continued to import the products.The affected products are: Jolly Rancher Hard Candy, Jolly Rancher 'Misfits' Gummies, Jolly Rancher Hard Candy Fruity 2 in 1, and Jolly Ranchers Berry Gummies.The food agency is advising people who have any of the listed products to not eat them and dispose of them at home. If consumers have any concerns, they are being asked to notify the Trading Standards department or environmental health department in the local authority they made the purchase from.The agency said it was asking enforcement authorities to make "immediate contact" with businesses which had been supplied with or received any of the products, and take action to ensure they were withdrawn from the market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
23 minutes ago
- Reuters
GSK says EU heath regulator reviewing expansion of RSV vaccine
June 13 (Reuters) - GSK (GSK.L), opens new tab said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age. A decision by the European Union's health regulator on the vaccine, already approved for certain age groups, is expected in the first half of 2026, GSK said.
Telegraph
29 minutes ago
- Telegraph
NHS patients to receive drug that destroys cancer from inside
A so-called 'Trojan Horse' drug that destroys blood cancer from within is set to be rolled out to thousands of NHS patients. The health service will be the first in the world to make the drug available to patients with multiple myeloma – an incurable cancer of the bone marrow. The drug, called belantamab mafadotin, was developed in the UK and has been dubbed a 'Trojan Horse' therapy because it tricks cancer cells into absorbing it before killing them from within. While the cancer is incurable, treatment is designed to extend people's lives by as much as possible while minimising the impact of side effects and on quality of life. In trials, cancer progression was delayed by three years on average in those taking the drug, which was three times longer than the most common treatment. Around 1,500 patients a year in England will benefit after the treatment was approved by the National Institute for Health and Care Excellence on Thursday. The drug will be offered to patients whose cancer has progressed or not responded to the first choice of treatment using another drug, lenalidomide. Patients who are prescribed the drug will receive it via an infusion once every three weeks in combination with two other cancer treatments.
The Guardian
43 minutes ago
- The Guardian
Blood cancer patients in England first in world to be offered ‘Trojan horse' drug
Thousands of patients in England with blood cancer will become the first in the world to be offered a pioneering 'Trojan horse' drug that sneaks inside cancer cells and wipes them out. In guidance published on Friday, the National Institute for Health and Care Excellence (Nice) gave the green light to belantamab mafodotin, which can halt the advance of multiple myeloma for three times as long as standard treatments. The targeted therapy, which is given as an infusion every three weeks with other cancer drugs, is a special type of antibody drug that targets and attaches to cancer cells. It has been described as a Trojan horse treatment because it works by being taken into a cancer cell and unleashing a high concentration of a lethal molecule to destroy the cell from inside. Prof Peter Johnson, NHS England's national clinical director for cancer, said the drug would be life-changing for patients and their families. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' he said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family.' About 1,500 patients a year in England with multiple myeloma, an incurable cancer of the bone marrow, will benefit from the treatment, also known as Blenrep and made by GlaxoSmithKline. Health officials said the drug would be offered to patients whose cancer had progressed or failed to respond to another first-line treatment. Shelagh McKinlay, the director of research and advocacy at the blood cancer charity Myeloma UK, said it was fantastic to see the NHS become the first healthcare system in the world to roll out the drug. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma,' she said. Paul Silvester, 60, from Sheffield, described the impact of the drug as amazing after he was diagnosed with myeloma in 2023. After the first treatment he received failed to stop his cancer progressing, he was given belantamab mafodotin through an early access programme at the Royal Hallamshire hospital. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. Trials suggest the treatment, in combination with bortezomib and dexamethasone, delays progression of the disease by an average of three years, compared with one year for patients taking the commonly used drug daratumumab along with the other treatments. Helen Knight, the director of medicines evaluation at Nice, said: 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' The health minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge 'Trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
